Drug Trial Radar · NCT06965413
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
285
Actual
Start
May 5, 2025
Primary completion
Sep 3, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 11, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or overweight with at least one weight-related comorbidity, but without diabetes mellitus (DM). The study comprises of a 4-week screening period; a 48-week core treatment period, where all participants will receive tirzepatide as background treatment and will be randomized to one of the 4 treatment arms; a 24-week treatment extension period, where participants will stop treatment with tirzepatide and a 24-week post-treatment follow-up (FU) period.
Conditions
- Obesity
- Overweight
- Overweight With One Weight Related Comorbidity
Interventions
RO7204239Drug
RO7204239 or matching placebo will be administered as per the schedule specified in the arms.
RO7204239 Matching PlaceboDrug
RO7204239 matching placebo will be administered as per the schedule specified in the arm.
TirzepatideDrug
Tirzepatide will be administered as per the schedule specified in the arms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Body WeightTime frame: Baseline, Week 48
Locations
35 sites in 4 countries. Site status is shown where the registry gives one.
Pinnacle Research Group
Anniston, Alabama
Encompass Clinical Research
Spring Valley, California
K2 Medical Research-Winter Garden
Clermont, Florida
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia
Accellacare of Duly Health and Care
Oak Lawn, Illinois
Rochester Clinical Research
Rochester, New York
Accellacare of Salisbury
Salisbury, North Carolina
Accellacare of Piedmont Healthcare
Statesville, North Carolina
Accellacare of Wilmington, LLC
Wilmington, North Carolina
Accellacare Research of Winston Salem
Winston-Salem, North Carolina
NexGen Research
Lima, Ohio
Accellacare of Bristol/ Internal Medicine & Pediatrics
Bristol, Tennessee
Accellacare of Knoxville
Knoxville, Tennessee
Clinical Research Associates
Nashville, Tennessee
Texas Diabetes & Endocrinology, P.A.
Austin, Texas
Juno Research, LLC
Houston, Texas
Consano Clinical Research
Shavano Park, Texas
Velocity Clinical Research (Impact Research Institute)
Waco, Texas
Manassas Clinical Research Center
Manassas, Virginia
Ekamed sp. z o.o.
Lublin, Poland
ETG Warszawa
Warsaw, Poland
Centrum Medyczne ALL-MED
Krakow, Lesser Poland Voivodeship, Poland
Penta Hospials Badania Kliniczne Gdansk
Gdansk, Pomeranian Voivodeship, Poland
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Universitario Virgen de la Victoria
Málaga, Spain
Universidad de Sevilla - Hospital Universitario Virgen Macarena
Seville, Barcelona, Spain
Instituto De Investigacion Marques De Valdecilla (IDIVAL)
Santander, Cantabria, Spain
Hospital Vithas Nisa Sevilla
Castilleja de la Cuesta, Granada, Spain
Hospital San Rafael A Coruna
A Coruña, LA Coruna, Spain
Accellacare Warwickshire
Coventry, United Kingdom
Accellacare North London
Northwood, United Kingdom
Accellacare South London
Orpington, United Kingdom
Fylde Coast Clinical Research at Layton Medical Centre
Blackpool, Lancashire, United Kingdom
University Hospitals of Leicester NHS Trust - Leicester General Hospital (LGH)
Leicester, Leicestershire, United Kingdom
Accellacare Yorkshire
Shipley, Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.